Sunitinib enhances the antitumor responses of agonistic CD40- antibody by reducing MDSCs and synergistically improving endothelial activation and T-cell recruitment

Oncotarget

Volumn 7, Issue 31, 2016, Pages 50277-50289

  van Hooren, Luuk ^a   Georganaki, Maria ^a   Huang, Hua ^a   Mangsbo, Sara M ^a   Dimberg, Anna ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

CD40; Endothelial activation; MDSC; Sunitinib; T cell

Indexed keywords

CD40 LIGAND MONOCLONAL ANTIBODY; GLYCOPROTEIN P 15095; INTERCELLULAR ADHESION MOLECULE 1; SUNITINIB; VASCULAR CELL ADHESION MOLECULE 1; ANTINEOPLASTIC AGENT; CD11B ANTIGEN; CD40 ANTIGEN; INDOLE DERIVATIVE; MONOCLONAL ANTIBODY; PYRROLE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG MECHANISM; DRUG POTENTIATION; FIBROSARCOMA; LYMPHOCYTE MIGRATION; MALE; MELANOMA; MOUSE; MYELOID DERIVED SUPPRESSOR CELL; NONHUMAN; PROTEIN EXPRESSION; SUPPRESSOR CELL; T LYMPHOCYTE; AGONISTS; ANIMAL; C57BL MOUSE; DRUG EFFECTS; ENDOTHELIUM CELL; EXPERIMENTAL MELANOMA; IMMUNOLOGY; KAPLAN MEIER METHOD; METABOLISM; MORTALITY; MYELOID-DERIVED SUPPRESSOR CELL; TUMOR CELL LINE; UPREGULATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CD11B ANTIGEN; CD40 ANTIGENS; CELL LINE, TUMOR; DENDRITIC CELLS; DRUG SYNERGISM; ENDOTHELIAL CELLS; FIBROSARCOMA; INDOLES; INTERCELLULAR ADHESION MOLECULE-1; KAPLAN-MEIER ESTIMATE; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MYELOID-DERIVED SUPPRESSOR CELLS; PYRROLES; T-LYMPHOCYTES, CYTOTOXIC; UP-REGULATION; VASCULAR CELL ADHESION MOLECULE-1;

EID: 84981295233     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.10364     Document Type: Article

References (42)

1. Motz GT and Coukos G. Deciphering and reversing tumor immune suppression. Immunity. 2013; 39:61-73.
2. Hassan SB, Sorensen JF, Olsen BN and Pedersen AE. Anti-CD40-mediated cancer immunotherapy: an update of recent and ongoing clinical trials. Immunopharmacol Immunotoxicol. 2014; 36:96-104.
3. Mangsbo SM, Broos S, Fletcher E, Veitonmaki N, Furebring C, Dahlen E, Norlen P, Lindstedt M, Totterman TH and Ellmark P. The human agonistic CD40 antibody ADC-1013 eradicates bladder tumors and generates T-cell-dependent tumor immunity. Clin Cancer Res. 2015; 21:1115-1126.
4. Vonderheide RH, Flaherty KT, Khalil M, Stumacher MS, Bajor DL, Hutnick NA, Sullivan P, Mahany JJ, Gallagher M, Kramer A, Green SJ, O'Dwyer PJ, et al. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol. 2007; 25:876-883.
5. Todryk SM, Tutt AL, Green MH, Smallwood JA, Halanek N, Dalgleish AG and Glennie MJ. CD40 ligation for immunotherapy of solid tumours. J Immunol Methods. 2001; 248:139-147.
6. van Mierlo GJ, den Boer AT, Medema JP, van der Voort EI, Fransen MF, Offringa R, Melief CJ and Toes RE. CD40 stimulation leads to effective therapy of CD40(-) tumors through induction of strong systemic cytotoxic T lymphocyte immunity. Proc Natl Acad Sci U S A. 2002; 99:5561-5566.
7. Vonderheide RH and Glennie MJ. Agonistic CD40 antibodies and cancer therapy. Clin Cancer Res. 2013; 19:1035-1043.
8. Flaxenburg JA, Melter M, Lapchak PH, Briscoe DM and Pal S. The CD40-induced signaling pathway in endothelial cells resulting in the overexpression of vascular endothelial growth factor involves Ras and phosphatidylinositol 3-kinase. J Immunol. 2004; 172:7503-7509.
9. Pan PY, Ma G, Weber KJ, Ozao-Choy J, Wang G, Yin B, Divino CM and Chen SH. Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer. Cancer Res. 2010; 70:99-108.
10. Lanitis E, Irving M and Coukos G. Targeting the tumor vasculature to enhance T-cell activity. Curr Opin Immunol. 2015; 33:55-63.
11. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005; 307:58-62.
12. Bouzin C, Brouet A, De Vriese J, Dewever J and Feron O. Effects of vascular endothelial growth factor on the lymphocyte-endothelium interactions: identification of caveolin-1 and nitric oxide as control points of endothelial cell anergy. J Immunol. 2007; 178:1505-1511.
13. Dirkx AE, Oude Egbrink MG, Kuijpers MJ, van der Niet ST, Heijnen VV, Bouma-ter Steege JC, Wagstaff J and Griffioen AW. Tumor angiogenesis modulates leukocytevessel wall interactions in vivo by reducing endothelial adhesion molecule expression. Cancer Res. 2003; 63:2322-2329.
14. Dirkx AE, Oude Egbrink MG, Castermans K, van der Schaft DW, Thijssen VL, Dings RP, Kwee L, Mayo KH, Wagstaff J, Bouma-ter Steege JC and Griffioen AW. Antiangiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumors. FASEB J. 2006; 20:621-630.
15. Huang H, Langenkamp E, Georganaki M, Loskog A, Fuchs PF, Dieterich LC, Kreuger J and Dimberg A. VEGF suppresses T-lymphocyte infiltration in the tumor microenvironment through inhibition of NF-kappaBinduced endothelial activation. FASEB J. 2015; 29:227-238.
16. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, Murray LJ, Carver J, Chan E, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and plateletderived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res. 2003; 9:327-337.
17. Ozao-Choy J, Ma G, Kao J, Wang GX, Meseck M, Sung M, Schwartz M, Divino CM, Pan PY and Chen SH. The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res. 2009; 69:2514-2522.
18. Kwilas AR, Donahue RN, Tsang KY and Hodge JW. Immune consequences of tyrosine kinase inhibitors that synergize with cancer immunotherapy. Cancer Cell Microenviron. 2015; 2.
19. Sandin LC, Orlova A, Gustafsson E, Ellmark P, Tolmachev V, Totterman TH and Mangsbo SM. Locally delivered CD40 agonist antibody accumulates in secondary lymphoid organs and eradicates experimental disseminated bladder cancer. Cancer Immunol Res. 2014; 2:80-90.
20. Heine A, Held SA, Daecke SN, Riethausen K, Kotthoff P, Flores C, Kurts C and Brossart P. The VEGF-Receptor Inhibitor Axitinib Impairs Dendritic Cell Phenotype and Function. PLoS One. 2015; 10:e0128897.
21. Jaini R, Rayman P, Cohen PA, Finke JH and Tuohy VK. Combination of sunitinib with anti-tumor vaccination inhibits T-cell priming and requires careful scheduling to achieve productive immunotherapy. Int J Cancer. 2014; 134:1695-1705.
22. Inaba K, Inaba M, Witmer-Pack M, Hatchcock K, Hodes R and Steinman RM. Expression of B7 costimulator molecules on mouse dendritic cells. Adv Exp Med Biol. 1995; 378:65-70.
23. Vasudev NS and Reynolds AR. Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions. Angiogenesis. 2014; 17:471-494.
24. Marvel D and Gabrilovich DI. Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected. J Clin Invest. 2015; 125:3356-3364.
25. Shojaei F, Wu X, Malik AK, Zhong C, Baldwin ME, Schanz S, Fuh G, Gerber HP and Ferrara N. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat Biotechnol. 2007; 25:911-920.
26. Haverkamp JM, Smith AM, Weinlich R, Dillon CP, Qualls JE, Neale G, Koss B, Kim Y, Bronte V, Herold MJ, Green DR, Opferman JT and Murray PJ. Myeloid-derived suppressor activity is mediated by monocytic lineages maintained by continuous inhibition of extrinsic and intrinsic death pathways. Immunity. 2014; 41:947-959.
27. Gabrilovich DI, Ostrand-Rosenberg S and Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol. 2012; 12:253-268.
28. Corzo CA, Cotter MJ, Cheng P, Cheng F, Kusmartsev S, Sotomayor E, Padhya T, McCaffrey TV, McCaffrey JC and Gabrilovich DI. Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells. J Immunol. 2009; 182:5693-5701.
29. Kroon BK, de Bruijn R, Prevoo W, Horenblas S, Powles T and Bex A. Probability of downsizing primary tumors of renal cell carcinoma by targeted therapies is related to size at presentation. Urology. 2013; 81:111-115.
30. Yuasa T, Urakami S, Yamamoto S, Yonese J, Nakano K, Kodaira M, Takahashi S, Hatake K, Inamura K, Ishikwa Y and Fukui I. Tumor size is a potential predictor of response to tyrosine kinase inhibitors in renal cell cancer. Urology. 2011; 77:831-835.
31. Tsuchiya N, Yuasa T, Maita S, Narita S, Inoue T, Numakura K, Saito M, Satoh S, Yonese J and Habuchi T. Organ-specific and tumor-size-dependent responses to sunitinib in clear cell renal cell carcinoma. BMC Urol. 2014; 14:26.
32. Kim S, Ding W, Zhang L, Tian W and Chen S. Clinical response to sunitinib as a multitargeted tyrosine-kinase inhibitor (TKI) in solid cancers: a review of clinical trials. Onco Targets Ther. 2014; 7:719-728.
33. Olsson AK, Dimberg A, Kreuger J and Claesson-Welsh L. VEGF receptor signalling-in control of vascular function. Nat Rev Mol Cell Biol. 2006; 7:359-371.
34. Griffioen AW, Damen CA, Blijham GH and Groenewegen G. Tumor angiogenesis is accompanied by a decreased inflammatory response of tumor-associated endothelium. Blood. 1996; 88:667-673.
35. Griffioen AW, Damen CA, Martinotti S, Blijham GH and Groenewegen G. Endothelial intercellular adhesion molecule-1 expression is suppressed in human malignancies: the role of angiogenic factors. Cancer Res. 1996; 56:1111-1117.
36. Shrimali RK, Yu Z, Theoret MR, Chinnasamy D, Restifo NP and Rosenberg SA. Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res. 2010; 70:6171-6180.
37. Selvaraj S, Raundhal M, Patidar A and Saha B. Anti-VEGF antibody enhances the antitumor effect of CD40. Int J Cancer. 2014; 135:1983-1988.
38. Hong J, Tobin NP, Rundqvist H, Li T, Lavergne M, Garcia-Ibanez Y, Qin H, Paulsson J, Zeitelhofer M, Adzemovic MZ, Nilsson I, Roswall P, Hartman J, et al. Role of Tumor Pericytes in the Recruitment of Myeloid-Derived Suppressor Cells. J Natl Cancer Inst. 2015; 107.
39. Roland CL, Lynn KD, Toombs JE, Dineen SP, Udugamasooriya DG and Brekken RA. Cytokine levels correlate with immune cell infiltration after anti-VEGF therapy in preclinical mouse models of breast cancer. PLoS One. 2009; 4:e7669.
40. Rodriguez PC, Ernstoff MS, Hernandez C, Atkins M, Zabaleta J, Sierra R and Ochoa AC. Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res. 2009; 69:1553-1560.
41. Ko JS, Zea AH, Rini BI, Ireland JL, Elson P, Cohen P, Golshayan A, Rayman PA, Wood L, Garcia J, Dreicer R, Bukowski R and Finke JH. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res. 2009; 15:2148-2157.
42. Byrne KT, Leisenring NH, Bajor DL and Vonderheide RH. CSF-1R-Dependent Lethal Hepatotoxicity When Agonistic CD40 Antibody Is Given before but Not after Chemotherapy. J Immunol. 2016.